Frontiers in Pharmacology
September 30, 2026
Kacper Żełabowski, Tomasz Wieczorek, Adam Hamed
Stroboscopic light stimulation (SLS) and psilocybin each induce altered states whose phenomenology and neurophysiology partly overlap, including posterior alpha-band changes and visual imagery. The two states engage the alpha band through different operations - pharmacological suppression under psilocybin and frequency-selective visual drive under SLS. We formalize their possible interaction...
JAMA Network Open
September 29, 2026
Otto Simonsson, Melissa Bradley, Joshua Curtis Black et al.
This cross-sectional study describes health outcomes attributed to recent use of psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a nationally representative survey of US adults.
International Journal of Innovative Technologies in Social Science
September 28, 2026
Klaudia Karolina Wójcik, Michal Kieres, Krzysztof Sebastian Habirek et al.
The article aims to compare receptor mechanisms related to neurotransmitters for some of the most widely used psychoactive substances - amphetamine, cocaine, ecstasy (MDMA), and psilocybin - and to link these mechanisms to cardiovascular effects, thermoregulation, and neurotoxicity. The review is based mainly on in vitro studies on transporters and receptors, animal models, and controlled...
Zenodo (CERN European Organization for Nuclear Research)
September 27, 2026
Andrea Vittorini
preprint
This hypothesis and perspective article proposes that dosing schedule should be treated as an independent pharmacological variable in psilocybin microdosing research. Existing controlled studies relevant to depression and mood have predominantly used intermittent schedules. The first dedicated randomized trial in major depressive disorder used 2 mg psilocybin once weekly and did not demonstrate...
medRxiv
September 23, 2026
Dominika Dojčánová, Filip Tylš, Marek Nikolič et al.
preprint
Music is a central component of psychedelic settings, yet little experimental work has examined how psilocybin and musical composition influence music-evoked emotional responses in healthy volunteers. This exploratory, double-blind, placebo-controlled study assessed these effects during the plateau phase of psilocybin and the corresponding time window in placebo sessions following oral...
Frontiers in Pharmacology
September 22, 2026
David Ernst Hogg, Jennifer Romanos, Jamie Albiez et al.
There is considerable interest in the concept that psychedelic compounds might facilitate reorganization of emotional processing with therapeutic benefit; in particular, amelioration of excessive focus on past, current and potential-future aversive events, a dominant emotional-cognitive state in stress-related affective disorders. Translational animal models can advance understanding of...
BMJ Open
September 22, 2026
Anna Kristina Eigenbrodt, Poul P Laigaard, Melika Hassani et al.
Recovery of consciousness after brain injury remains a major challenge in the intensive care unit (ICU), and pharmacological treatments that directly promote awakening from coma and other disorders of consciousness (DoC) are lacking. We hypothesise that simultaneously targeting the two core components of consciousness by pharmacological means-arousal with apomorphine and awareness with...
International Journal of Innovative Technologies in Social Science
September 21, 2026
Mateusz Gawin, Emilia Koziara, Mateusz Gadzina et al.
Major depressive disorder (MDD) is one of the leading causes of disability worldwide. A substantial proportion of patients fail to achieve remission through standard monoaminergic therapies, meeting the clinical criteria for treatment-resistant depression (TRD). TRD is associated with significant clinical morbidity and a profound economic burden on healthcare systems. This review evaluates the...
British Journal of Clinical Pharmacology
September 21, 2026
Anna Signor, Stefano Comai, Gianfranco Pasut et al.
AIMS: This study aimed to evaluate the safety, tolerability and pharmacokinetics of a novel oral modified-release psilocybin formulation (REL-P11) in normal-weight and overweight/obese healthy adults and to assess its suitability for controlled, subperceptual exposure, in light of emerging evidence supporting serotonergic modulation in metabolic disorders. METHODS: Simulation-based modelling...
Pharmaceuticals
September 21, 2026
Naama Levy‐Cooperman, Edward M. Sellers, Paul Glue et al.
Background/Objectives: Psilocybin shows therapeutic promise for several psychiatric disorders, but the acute perceptual and cognitive alterations produced by conventional doses (10–25 mg) require in-clinic supervision, which limits scalability. Whether the therapeutically relevant pharmacology of psilocybin can be safely separated from its hallucinogenic activity remains unresolved. To address...